Literature DB >> 17052695

Structure-function of alpha1-adrenergic receptors.

Dianne M Perez1.   

Abstract

The Easson-Stedman hypothesis provided the rationale for the first studies of drug design for the alpha(1)-adrenergic receptor. Through chemical modifications of the catecholamine core structure, the need was established for a protonated amine, a beta-hydroxyl on a chiral center, and an aromatic ring with substitutions capable of hydrogen bonding. After the receptors were cloned and three alpha(1)-adrenergic receptor subtypes were discovered, drug design became focused on the analysis of receptor structure and new interactions were uncovered. It became clear that alpha(1)- and beta-adrenergic receptors did not share stringent homology in the ligand-binding pocket but this difference has allowed for more selective drug design. Novel discoveries on allosterism and agonist trafficking may be used in the future design of therapeutics with fewer side effects. This review will explore past and current knowledge of the structure-function of the alpha(1)-adrenergic receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052695      PMCID: PMC2034198          DOI: 10.1016/j.bcp.2006.09.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  78 in total

1.  Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin.

Authors:  R A Dixon; B K Kobilka; D J Strader; J L Benovic; H G Dohlman; T Frielle; M A Bolanowski; C D Bennett; E Rands; R E Diehl; R A Mumford; E E Slater; I S Sigal; M G Caron; R J Lefkowitz; C D Strader
Journal:  Nature       Date:  1986 May 1-7       Impact factor: 49.962

Review 2.  Structure-activity relationships as a response to the pharmacological differences in beta-receptor ligands.

Authors:  C Labrid; I Rocher; O Guery
Journal:  Am J Hypertens       Date:  1989-11       Impact factor: 2.689

Review 3.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

4.  Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).

Authors:  M D Meyer; R J Altenbach; F Z Basha; W A Carroll; S Condon; S W Elmore; J F Kerwin; K B Sippy; K Tietje; M D Wendt; A A Hancock; M E Brune; S A Buckner; I Drizin
Journal:  J Med Chem       Date:  2000-04-20       Impact factor: 7.446

5.  Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation.

Authors:  D J Waugh; R J Gaivin; D S Damron; P A Murray; D M Perez
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

6.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

7.  Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists.

Authors:  D J Waugh; R J Gaivin; M J Zuscik; P Gonzalez-Cabrera; S A Ross; J Yun; D M Perez
Journal:  J Biol Chem       Date:  2001-04-30       Impact factor: 5.157

Review 8.  Molecular basis for the stereoselective interactions of catecholamines with alpha-adrenoceptors.

Authors:  J P Hieble; A Hehr; Y O Li; R R Ruffolo
Journal:  Proc West Pharmacol Soc       Date:  1998

9.  Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor.

Authors:  K Wieland; H M Zuurmond; C Krasel; A P Ijzerman; M J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  Receptor interactrions of imidazolines. VI. Significance of carbon bridge separating phenyl and imidazoline rings of tolazoline-like alpha adrenergic imidazolines.

Authors:  R R Ruffolo; E L Yaden; J E Waddell; R D Dillard
Journal:  J Pharmacol Exp Ther       Date:  1980-09       Impact factor: 4.030

View more
  12 in total

1.  Discovery of Quinazoline-Based Fluorescent Probes to α1-Adrenergic Receptors.

Authors:  Wei Zhang; Zhao Ma; Wenhua Li; Geng Li; Laizhong Chen; Zhenzhen Liu; Lupei Du; Minyong Li
Journal:  ACS Med Chem Lett       Date:  2015-03-30       Impact factor: 4.345

2.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

3.  Acupuncture Prevents the Impairment of Hippocampal LTP Through β1-AR in Vascular Dementia Rats.

Authors:  Ling-Yong Xiao; Xue-Rui Wang; Jing-Wen Yang; Yang Ye; Wen Zhu; Yan Cao; Si-Ming Ma; Cun-Zhi Liu
Journal:  Mol Neurobiol       Date:  2018-02-13       Impact factor: 5.590

Review 4.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

5.  Alpha(1D)-adrenergic receptor insensitivity is associated with alterations in its expression and distribution in cultured vascular myocytes.

Authors:  Lin-lin Fan; Shuang Ren; Hong Zhou; Ying Wang; Ping-xiang Xu; Jun-qi He; Da-li Luo
Journal:  Acta Pharmacol Sin       Date:  2009-12       Impact factor: 6.150

6.  Computational studies of the binding site of alpha1A-adrenoceptor antagonists.

Authors:  Minyong Li; Hao Fang; Lupei Du; Lin Xia; Binghe Wang
Journal:  J Mol Model       Date:  2008-07-15       Impact factor: 1.810

7.  Alpha-1 adrenergic receptor transactivates signal transducer and activator of transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes.

Authors:  Chang Han; William C Bowen; George K Michalopoulos; Tong Wu
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

Review 8.  Noradrenergic dysfunction in Alzheimer's disease.

Authors:  Mary Gannon; Pulin Che; Yunjia Chen; Kai Jiao; Erik D Roberson; Qin Wang
Journal:  Front Neurosci       Date:  2015-06-17       Impact factor: 4.677

9.  Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.

Authors:  Thomas A Munro; Xi-Ping Huang; Carmela Inglese; Maria Grazia Perrone; Ashlee Van't Veer; F Ivy Carroll; Cécile Béguin; William A Carlezon; Nicola A Colabufo; Bruce M Cohen; Bryan L Roth
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

Review 10.  Cardiovascular and Hepatic Toxicity of Cocaine: Potential Beneficial Effects of Modulators of Oxidative Stress.

Authors:  Manuela Graziani; Letizia Antonilli; Anna Rita Togna; Maria Caterina Grassi; Aldo Badiani; Luciano Saso
Journal:  Oxid Med Cell Longev       Date:  2015-12-28       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.